Ollin Biosciences Reveals Promising Results for OLN324 Against Faricimab in Eye Disease Trials Ollin Biosciences has released groundbreaking results showing OLN324 outperforming Faricimab in treating diabetic macular edema and wet AMD.

Ollin Biosciences Reveals Promising Results for OLN324 Against Faricimab in Eye Disease Trials #China #Suzhou #Innovent_Biologics #Ollin_Biosciences #IBI324

Innovent and Ollin Biosciences Achieve Milestone Results in Study of Diabetes-Related Eye Disease Treatment Innovent Biologics and Ollin Biosciences have demonstrated promising results in a head-to-head study of a new treatment for diabetic macular edema.

Innovent and Ollin Biosciences Achieve Milestone Results in Study of Diabetes-Related Eye Disease Treatment #None #San_Francisco #Innovent #Ollin_Biosciences #IBI324

Innovent's Partner Ollin Shares Promising Updates on Clinical Trials of IBI324 for Vision-Related Diseases Ollin Biosciences has reported significant advancements in the clinical trials of IBI324, a bispecific antibody targeting vision-threatening diseases. The findings present a potential breakthrough for patients with wAMD and DME.

Innovent's Partner Ollin Shares Promising Updates on Clinical Trials of IBI324 for Vision-Related Diseases #USA #San_Francisco #Innovent_Biologics #Ollin_Biosciences #IBI324